NESINA

Peak

alogliptin

NDAORALTABLET
Approved
Jan 2013
Lifecycle
Peak
Competitive Pressure
8/100
Clinical Trials
21

Mechanism of Action

glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) are released into the bloodstream from the small intestine in response to meals. These hormones cause insulin release from the pancreatic beta cells in a glucose-dependent manner but are inactivated by the DPP-4…

Clinical Trials (5)

NCT07093476Phase 3Recruiting

Efficacy and Safety of Add-On Therapy With Empagliflozin in Patients With Type 2 Diabetes on a Background of Alogliptin and Metformin

Started Jul 2025
171 enrolled
T2DMDiabete Type 2DM
NCT03794336Phase 4Completed

Efficacy and Safety of Alogliptin vs. Acarbose in Chinese Type 2 Diabetes Mellitus (T2DM) Patients With High CV Risk or CHD Treated With Aspirin and Inadequately Controlled With Metformin Monotherapy or Drug Naive

Started Jun 2019
1,293 enrolled
Type 2 Diabetes Mellitus
NCT03501277Phase 1Completed

A Study to Determine the Bioequivalence of Alogliptin and Pioglitazone When Administered as Individual Tablets and as Fixed-Dose Combination (FDC)-SYR-322-4833 BL Tablets to Healthy Russian Participants

Started May 2018
72 enrolled
Healthy Volunteers
NCT03042325Phase 4Withdrawn

Safety and Efficacy of Alogliptin in Indian Participants With Type 2 Diabetes Mellitus

Started Jul 2017
0
Diabetes Mellitus, Type 2
NCT02823808Phase 4Unknown

Effect of Alogliptin/Pioglitazone on the Preservation of Long-term Beta-cell Function

Started Jul 2017
96 enrolled
Diabetes

Loss of Exclusivity

LOE Date
Jun 16, 2029
40 months away
Patent Expiry
Jun 16, 2029
Exclusivity Expiry
Jul 27, 2026

Patent Records (2)

Patent #ExpiryTypeUse Code
7807689
Jun 27, 2028
SubstanceProduct
U-1337
8697125
Jun 16, 2029
Product